SCHEMBL6473264

SCHEMBL6473264

CC(CNS(=O)(=O)C(C)C)Oc1ccc(-c2ccc(CCNS(C)(=O)=O)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 10/20 0.68
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA5A P35218 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GRIA1 P42261 1/20 0.38
GRIA2 P42262 1/20 0.38
GRIA3 P42263 1/20 0.38
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38
F10 P00742 1/20 0.37
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473900 0.94 GRIA4 (0.58) GRIA4CA12CA1CA2CA5A
SCHEMBL6480388 0.88 GRIA4 (0.51) GRIA4SMN1; SMN2GRIA1GRIA2GRIA3
SCHEMBL6473736 0.86 GRIA4 (0.51) GRIA4CA12CA1CA2CA5A
SCHEMBL6482318 0.85 GRIA4 (0.53) GRIA4GRIA1GRIA2GRIA3
SCHEMBL6482278 0.85 ACACB (0.53) GRIA4ALDH1A1SMN1; SMN2
SCHEMBL6473271 0.85 GRIA4 (0.49) GRIA4CA12CA1CA2CA5A
Hydrochloric Acid SCHEMBL6480371 0.84 MAOB (0.48) GRIA4GRIA1GRIA2GRIA3
SCHEMBL6481825 0.84 GRIA4 (0.48) GRIA4CA12CA1CA2CA9
SCHEMBL6475842 0.83 GRIA4 (0.46) GRIA4GRIA1GRIA2GRIA3
SCHEMBL6766132 0.82 GRIA4 (0.48) GRIA4CA12CA1CA2CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885CA12 2263/4885CA1 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.